Syntagon Restructures to Further Improve Drug Substance Development Offering
Leading contract research provider, Syntagon, is set to implement a restructuring programme designed to further improve its offering to customers in the field of drug substance development.Syntagon’s Sweden-based operations (Syntagon AB) will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Group’s Latvian site (SIA Syntagon Baltic) will ramp up its capacity and know-how within the field of preclinical and clinical deliveries of drug substances. “The reorganisation will enable Syntagon to build